Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK.
Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.
AAPS J. 2020 May 21;22(4):75. doi: 10.1208/s12248-020-00449-w.
Excipients are major components of oral solid dosage forms, and changes in their critical material attributes (excipient variability) and/or amount (excipient variation) in pharmaceutical formulations may present a challenge for product performance. Understanding the biopharmaceutical factors affecting excipient performance is recommended for the successful implementation of excipient variability on Quality by Design (QbD) approaches. The current study investigated the impact of magnesium stearate (MgSt) variability on the apparent solubility of drugs with a wide range of physicochemical properties (drug ionization, drug lipophilicity, drug aqueous solubility). Compendial and biorelevant media were used to assess the role of gastrointestinal (GI) conditions on the excipient effects on drug apparent solubility. The lipophilic nature of MgSt decreased the apparent solubility of most compounds. The reduction in drug apparent solubility was more pronounced for highly soluble and/or highly ionized drugs and in presence of more highly crystalline or smaller particle size MgSt. The use of multivariate data analysis revealed the critical physicochemical and biopharmaceutical factors and the complex nature of excipient variability on the reduction in drug apparent solubility. The construction of a roadmap combining drug, excipient and medium characteristics allowed the identification of the cases where the presence of excipient or excipient variability may present risks for oral drug performance.
辅料是口服固体制剂的主要成分,其关键材料属性(辅料变异性)和/或数量(辅料变化)的变化可能会对产品性能造成挑战。为了成功实施基于设计的质量(QbD)方法中的辅料变异性,建议了解影响辅料性能的生物制药因素。本研究考察了硬脂酸镁(MgSt)变异性对具有广泛物理化学性质(药物离解、药物亲脂性、药物水溶解度)的药物表观溶解度的影响。采用法定和生物相关介质来评估胃肠道(GI)条件对辅料对药物表观溶解度影响的作用。MgSt 的亲脂性降低了大多数化合物的表观溶解度。对于高溶解度和/或高离解的药物,以及在存在更多结晶或更小粒径的 MgSt 时,药物表观溶解度的降低更为明显。多变量数据分析的应用揭示了关键的物理化学和生物制药因素以及辅料变异性对药物表观溶解度降低的复杂性质。通过结合药物、辅料和介质特性构建路线图,可以确定辅料或辅料变异性存在可能会对口服药物性能带来风险的情况。